Tag: M.W:100-200

The molecularity of an elementary reaction is the number of molecules that collide during that step in the mechanism., 22766-68-322766-68-3, If there is only a single reactant molecule in an elementary reaction, that step is designated as unimolecular. 22766-68-3, name is Ethyl quinuclidine-4-carboxylate. A new synthetic method of this compound is introduced below.

Step 1. A solution of 4-carbethoxyquinuclidine (10.92 g) in THF (155 mL) was treated at-780C with borane-THF (1.0 M, 77.5 mL). The resulting mixture was stirred at -78C for 4 h, then treated with water (50 mL), warmed to room temperature and stirred for an additional hour. The reaction mixture was diluted with ethyl acetate and the aqueous phase was separated and extracted with two further portions of ethyl acetate. The combined organic layers were washed with brine- (twice), dried (MgSO4), filtered and evaporated in vacuo. Purification by silica gel chromatography (eluting with cyclohexane-ethyl acetate [1 :0 to 1 :1]) gave 1-boranyl-1-aza-bicyclo[2.2.2]octane-4- carboxylic acid ethyl ester (7.12 g, 61%) as an off-white solid. 1H NMR (400 MHz, CDCI3) delta 4.16 (2H1 q, J = 6.9), 3.10-3.05 (6H1 m), 1.98-1.93 (6H, m), 1.26 (3H, t, J = 6.9).

Thank you very much for taking the time to read this article. If you are also interested in other aspects of Ethyl quinuclidine-4-carboxylate, , you can also browse my other articles.

Reference£º
Patent; ARGENTA DISCOVERY LIMITED; WO2008/99186; (2008); A1;,
Quinuclidine – Wikipedia
Quinuclidine | C7H13N | ChemSpider

40117-63-3, One of the major reasons is to use measurements of the macroscopic properties of a system, the rate of change in the concentration of reactants or products with time, to discover the sequence of events that occur at the molecular level. 40117-63-3, introduce a new downstream synthesis route.

Step 5: (S)-4-((1-(5-(2-methoxyquinolin-1-ium-3-yl)-JH-imidazol-2-yl)- 7-(methylamino)- 7-oxoheptyl)carbamoyl)quinuclidin-1-ium mono L-tartrate salt (A5) A solution of 4-carboxyquinuclidin-1-ium chlorhydrate (1.3 eq.) in DMF (0.2 M) was treated with TBTU (1.3 eq.) and NMM (2.6 eq.). The reaction mixture was stirred at room temperature for 10 minutes and then added to a solution of A4 in DMF (0.2 M). The reaction was stirred at RT for 2 h and subsequently was purified by RP-HPLC (Acetonitrile/H20 + 0.1 % TFA). Theproduct was obtained as TFA salt which was partitioned between DCM and sat. aq. NaHCO3. The organic phase was separated, dried over Na2504 and concentrated under reduced pressure. The resulting syrup was dissolved in acetonitrile/H20 (2:3) and treated with L-tartaric acid (1 eq.). The resulting solution was lyophilized to obtain the title compound. 1H-NMR (400 MHz, 300 K, DMSO-d6) oe 8.73 (br s, 1H), 7.94 (t, 2H, J 9.6 Hz), 7.76 (d, 1H, J 8.0 Hz), 7.67 (br s,1H), 7.60 (m, 2H), 7.42 (t, 1H, J8.0 Hz), 5.02 (m, 1H), 4.13 (s, 3H), 3.93 (s, 2H), 3.18 (t, 6H, J7.2 Hz), 2.54 (d, 3H, J4.4 Hz), 2.05-1.91 (m, 8H), 1.51-1.23 (m, 8H). MS (ESj C29H38N603:519 (M+H).

This molecular description is the mechanism of the reaction; it describes how individual atoms, ions, or molecules interact to form particular products.If you are interested, you can also browse other articles of Quinuclidine-4-carboxylic acid hydrochloride, , We look forward to the emergence of more reaction modes in the future.

Reference£º
Patent; IRBM SCIENCE PARK S.P.A.; C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING; ALTAMURA, Sergio; BIANCOFIORE, Ilaria; BRESCIANI, Alberto; FERRIGNO, Federica; HARPER, Steven; LAUFER, Ralph; ONTORIA ONTORIA, Jesus Maria; MALANCONA, Savina; MONTEAGUDO, Edith; NIZI, Emanuela; ORSALE, Maria Vittoria; PONZI, Simona; PAONESSA, Giacomo; SUMMA, Vincenzo; VENEZIANO, Maria; WO2014/67985; (2014); A1;,
Quinuclidine – Wikipedia
Quinuclidine | C7H13N | ChemSpider

22766-68-3, One of the major reasons is to use measurements of the macroscopic properties of a system, the rate of change in the concentration of reactants or products with time, to discover the sequence of events that occur at the molecular level. 22766-68-3, introduce a new downstream synthesis route.

Example 13: Preparation of 4-[cyano(di-2-thienyl)methyl]-1-[3- (DhenVIoxVlDroDVIl-1-azoniabicvclo [2.2.210ctane bromide;. 1-Azabicyclof2. 2. 2 Joct-4-yl(di-2-thienyl)methanol; A solution of 2-thienyllithium (1.0 M in THF, 13.0 mL, 13 mmol) was chilled down to -30 C under Ar. Ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (0.77 g, 4.20 mmol) in THF (12 mL) was slowly added to the 2-thienyllithium at-30 C over 40 min. The reaction was allowed to warm up to room temperature for overnight. The reaction was quenched with H20 and then diluted with EtOAC, hexane and DCM causing a solid to crash out of solution. The solid was filtered off, resulting in the desired compound (0.9132 g, 71.3%). EI-MS m/z 306 (M+) Rt (1.33 min).

This molecular description is the mechanism of the reaction; it describes how individual atoms, ions, or molecules interact to form particular products.If you are interested, you can also browse other articles of Ethyl quinuclidine-4-carboxylate, , We look forward to the emergence of more reaction modes in the future.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2005/112644; (2005); A2;,
Quinuclidine – Wikipedia
Quinuclidine | C7H13N | ChemSpider

Reference of 827-61-2, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 827-61-2, Name is Quinuclidin-3-yl acetate, molecular formula is C9H15NO2. In a Patent£¬once mentioned of 827-61-2

Process for preparing quinuclidine enantiomers

A new composition of matter, (+) 3-acetoxy- quinuclidine and its salts, ophthalmic compositions comprising this compound or any of its physiologically acceptable salts in a suitable carrier such as a phosphate buffer, and a process of preparation of the active ingredients, which comprises esterifying quinuclidinol so as to obtain racemic 3-lower-alkoxy quinuclidine, subjecting same to enzymatic hydrolysis by a cholinesterase so as to selectively hydrolyze the (-) isomer, separating the unchanged (+) lower-alkoxy quinuclidine, hydrolyzing the latter and esterifying it to the desired compound. Amongst various homolophes the preferred compound is (+)3-acetoxy quinuclidine as this is pharmaceutically the most potent one.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 827-61-2, and how the biochemistry of the body works.Reference of 827-61-2

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H43N | ChemSpider

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride. In a document type is Article, introducing its new discovery., Product Details of 123536-14-9

5-SUBSTITUTED IMIDAZOLES

Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Computed Properties of C7H16Cl2N2, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about Computed Properties of C7H16Cl2N2

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H102N | ChemSpider

An article , which mentions 5291-32-7, molecular formula is C10H17NO3. The compound – APR-246 played an important role in people’s production and life., Safety of APR-246

NEW STRATEGIES FOR TREATING MELANOMA

The present invention relates to a p53-activating agent capable of transferring wild-type tumor protein p53 (p53) from an inactive conformation into an active conformation capable of inducing apoptosis, for use in the treatment of melanoma, wherein said p53-activating agent is administered simultaneously or sequentially with a BRAF-inhibiting agent capable of inhibiting activity of serine/threonine-protein kinase B-Raf (BRAF) comprising an activating mutation.

Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. I hope my blog about is helpful to your research. Safety of APR-246

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H166N | ChemSpider

5291-32-7, Name is APR-246, belongs to quinuclidine compound, is a common compound. name: APR-246In an article, once mentioned the new application about 5291-32-7.

USE OF ERIBULIN AND 3-QUINUCLIDINONE DERIVATIVES IN THE TREATMENT OF CANCER

The invention features methods for treating and preventing cancer (e.g., a p53-mutated cancer) in a patient in need thereof by administering eribulin (e.g., eribulin mesylate) in combination with a 3-quinuclidinone derivative (e.g., PRIMA-1 or PRIMA-1MET).

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 5291-32-7

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H164N | ChemSpider

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride. In a document type is Article, introducing its new discovery., Product Details of 123536-14-16

Comparison of the muscarinic receptor binding activity of some tertiary amines and their quaternary ammonium analogues

A series of tertiary amines and their N-methyl quaternary salts were examined for their ability to inhibit specific [3H]3-quinuclidinyl benzilate binding to rat brain muscarinic receptors. The more flexible tertiary amines, like dimethylaminoethyl acetate, were less potent than their respective quaternary ammonium analogues, while rigid tertiary amines, like aceclidine, were more potent than their quaternary derivatives. The competition curves of most of the compounds were adequately described by a two-site binding equation. A good correlation between pharmacological activity and the high-affinity dissociation constant was observed. The influence of pH in the competitive inhibition of [3H]3-quinuclidinyl benzilate binding by arecoline and scopolamine was also examined. The potency of these amines declined relative to that of their N-methyl derivatives as the pH increased from 8.90 to 9.0, suggesting that it is primarily the protonated form of arecoline and scopolamine which interacts with the muscarinic receptor.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, Application In Synthesis of Quinuclidin-3-yl acetate, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about Application In Synthesis of Quinuclidin-3-yl acetate

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H56N | ChemSpider

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. COA of Formula: C7H16Cl2N2, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 123536-14-1, name is (R)-3-Aminoquinuclidine dihydrochloride. In an article£¬Which mentioned a new discovery about 123536-14-1

Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

The invention provides compounds of formula (I) wherein n, A, R1, R2 and R3 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.COA of Formula: C7H16Cl2N2. In my other articles, you can also check out more blogs about 123536-14-1

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H111N | ChemSpider

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride. In a document type is Article, introducing its new discovery., Product Details of 123536-14-12

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and noxa

Targeting p53 by the small-molecule PRIMA-1Met/APR-246 has shown promising preclinical activity in various cancer types.However, the mechanism of PRIMA-1Met-induced apoptosis is not completely understood and its effect on multiple myeloma cells is unknown. In this study, we evaluated antitumor effect of PRIMA-1Met alone or its combination with current antimyeloma agents in multiple myeloma cell lines, patient samples, and a mouse xenograft model. Results of our study showed that PRIMA-1Met decreased the viability of multiple myeloma cells irrespective of p53 status, with limited cytotoxicity toward normal hematopoietic cells. Treatment of multiple myeloma cells with PRIMA-1Met resulted in induction of apoptosis, inhibition of colony formation, and migration. PRIMA-1Met restored wild-type conformation of mutant p53 and induced activation of p73 upregulating Noxa and downregulating Mcl-1 without significant modulation of p53 level. siRNAmediated silencing of p53 showed a little effect on apoptotic response of PRIMA-1Met, whereas knockdown of p73 led to substantial attenuation of apoptotic activity in multiple myeloma cells, indicating that PRIMA-1Met- induced apoptosis is, at least in part, p73-dependent.Importantly, PRIMA-1Met delayed tumor growth and prolonged survival of mice bearing multiple myeloma tumor. Furthermore, combined treatment of PRIMA-1Met with dexamethasone or doxorubicin displayed synergistic effects in both multiple myeloma cell lines and primary multiple myeloma samples. Consistent with our in vitro observations, cotreatment with PRIMA-1Met and dexamethasone resulted in enhanced antitumor activity in vivo. Our study for the first time shows antimyeloma activity of PRIMA-1Met and provides the rationale for its clinical evaluation in patients with multiple myeloma, including the high-risk group with p53 mutation/deletion. Mol Cancer Ther; 12(11); 2331-41.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 5291-32-7

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H174N | ChemSpider